These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Emerging biological therapies for the treatment of myelodysplastic syndromes. Zeidan AM; Stahl M; Komrokji R Expert Opin Emerg Drugs; 2016 Sep; 21(3):283-300. PubMed ID: 27486848 [TBL] [Abstract][Full Text] [Related]
6. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities. Abou Zahr A; Bernabe Ramirez C; Wozney J; Prebet T; Zeidan AM Expert Rev Hematol; 2016; 9(4):377-88. PubMed ID: 26734762 [TBL] [Abstract][Full Text] [Related]
7. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Stahl M; Zeidan AM Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851 [TBL] [Abstract][Full Text] [Related]
8. The emerging role of immune checkpoint based approaches in AML and MDS. Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300 [TBL] [Abstract][Full Text] [Related]
9. [Recent advances in the treatment of myelodysplastic syndromes]. Gelsi-Boyer V; Vey N Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027 [TBL] [Abstract][Full Text] [Related]
10. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1 Bewersdorf JP; Xie Z; Bejar R; Borate U; Boultwood J; Brunner AM; Buckstein R; Carraway HE; Churpek JE; Daver NG; Porta MGD; DeZern AE; Fenaux P; Figueroa ME; Gore SD; Griffiths EA; Halene S; Hasserjian RP; Hourigan CS; Kim TK; Komrokji R; Kuchroo VK; List AF; Loghavi S; Majeti R; Odenike O; Patnaik MM; Platzbecker U; Roboz GJ; Sallman DA; Santini V; Sanz G; Sekeres MA; Stahl M; Starczynowski DT; Steensma DP; Taylor J; Abdel-Wahab O; Xu ML; Savona MR; Wei AH; Zeidan AM Blood Rev; 2023 Jul; 60():101072. PubMed ID: 36934059 [TBL] [Abstract][Full Text] [Related]
12. Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy. Zahid MF; Patnaik MM; Gangat N; Hashmi SK; Rizzieri DA Eur J Haematol; 2016 Oct; 97(4):313-20. PubMed ID: 27147278 [TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Barzi A; Sekeres MA Cleve Clin J Med; 2010 Jan; 77(1):37-44. PubMed ID: 20048028 [TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Garcia-Manero G Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090 [TBL] [Abstract][Full Text] [Related]
15. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes. Duetz C; Cucchi DGJ; Polak TB; Janssen JJWM; Ossenkoppele GJ; Estey EH; van de Loosdrecht AA Br J Haematol; 2022 Jan; 196(2):329-335. PubMed ID: 34632583 [TBL] [Abstract][Full Text] [Related]
16. New approaches to the treatment of myelodysplasia. List AF Oncologist; 2002; 7 Suppl 1():39-49. PubMed ID: 11961208 [TBL] [Abstract][Full Text] [Related]
17. Emerging treatment options for patients with high-risk myelodysplastic syndrome. Bewersdorf JP; Carraway H; Prebet T Ther Adv Hematol; 2020; 11():2040620720955006. PubMed ID: 33240476 [TBL] [Abstract][Full Text] [Related]
18. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Zeidan AM; Shallis RM; Wang R; Davidoff A; Ma X Blood Rev; 2019 Mar; 34():1-15. PubMed ID: 30314642 [TBL] [Abstract][Full Text] [Related]
19. More is better: combination therapies for myelodysplastic syndromes. Ornstein MC; Mukherjee S; Sekeres MA Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727 [TBL] [Abstract][Full Text] [Related]
20. Novel agents for the management of myelodysplastic syndromes. Meletis J; Viniou N; Terpos E Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]